Altria's (MO) low-risk and oral tobacco offerings are gaining popularity. Moreover, high pricing for tobacco products is an upside.
This research idea must come with a health warning, not least because Clinigen doled out a trading alert only last week and the shares promptly plunged by 25pc in a day. There is always the chance that there could be further disappointment ahead – profit warnings do tend to come in threes, as the old saying goes, and the company’s short-term fortunes do to some degree depend on Covid-19. Nevertheless, it is tempting to take a closer look at the speciality pharmaceuticals and services business no
Vype maker BAT attracts 1.4m new vape users in three monthsLondon-headquartered tobacco company aims for 50 million users of non-cigarette products by 2025 An advert for Vype, BAT’s flagship vaping brand. Photograph: BAT